Molecular Switches in Cell Signaling: Drug Development
The sales of the top 20 drugs targeting molecular switches have exceeded $30 billion, highlighting the growing importance of...
eClinical Tech News
Quanta FDA Clearance for QTX3544 KRAS Inhibitor & Pipeline Updates
Quanta Therapeutics announced advancements in its KRAS-directed drug candidates, including FDA IND clearance for QTX3544, a G12V-preferring multi-KRAS inhibitor,...
Aerwave’s Ultrasound Therapy Shows Promise for COPD & Asthma
AerWave Medical completed its first-in-human feasibility study of a novel ultrasound lung denervation therapy for chronic obstructive pulmonary disease...
Bitterroot Bio Announces Positive Phase 1 Data for BRB-002
Bitterroot Bio announced positive Phase 1 results for BRB-002, a first-in-class immune-modulating protein therapy targeting CD47 for atherosclerotic cardiovascular...
Cassava Sciences Slashes Workforce by 33%
Cassava Sciences announced a 33% workforce reduction, cost-cutting measures, and anticipated topline data release from its Phase 3 REFOCUS-ALZ...
Micron Secures $43M for Measles, Rubella & Needle-Free Infant Vaccines
Micron Biomedical received a $7.5 million grant from the Bill & Melinda Gates Foundation, bringing total funding from the...
Solid Biosciences Announces FDA IND Clearance for First-in-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich’s Ataxia
Solid Biosciences has received FDA clearance for its Investigational New Drug (IND) application for SGT-212, a gene therapy designed...
Sana Biotechnology Shows Positive Results in Type 1 Diabetes Study
Sana Biotechnology announced positive initial results from a first-in-human study involving a patient with type 1 diabetes. The study,...
Cyclarity Therapeutics Gets FDA Nod for First Human Clinical Trial
Cyclarity Therapeutics has received regulatory approval to commence its first-in-human clinical trial for UDP-003 at CMAX in Australia, partnered...
Biomea Fusion Reveals Promising Preclinical Data on Icovamenib Combination
Biomea Fusion announced positive preclinical data for icovamenib combined with semaglutide, a GLP-1 receptor agonist, in treating type 2...